FDA Commissioner Marty Makary announced on March 3, 2026, that the agency had issued 30 warning letters to telehealth companies for making false or misleading claims about compounded semaglutide and tirzepatide products on their websites. The letters, physically dispatched February 20, cite promotional language implying compounded versions are identical to FDA-approved drugs and private-label branding that conceals which pharmacy actually prepared the product. Companies received 15 business days to submit corrective responses or face seizure, injunction, or further legal action without additional notice, as detailed by Patient Care Online.
Makary called the action "a new era of enforcement" and warned that compounders "should not try to compound drugs in a way that circumvents FDA's approval process." The letters represent the second wave of telehealth-targeted warnings since the agency began its direct-to-consumer advertising crackdown in September 2025. Over the preceding six months, FDA had dispatched thousands of warning letters to pharmaceutical and telehealth firms, a volume exceeding the total sent over the entire prior decade, Reuters reported.
Marketing claims under the FD&C Act
Figure 1: The FDA's escalating warning-letter campaign against telehealth marketing of compounded GLP-1 peptides proceeds alongside a pending 503A bulks-list decision that could expand legal compounding of certain peptides.
The specific violations fall under Sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act, which render a drug misbranded when its advertising is false or misleading. FDA objected to website copy presenting compounded semaglutide or tirzepatide as therapeutically equivalent to Wegovy, Zepbound, Ozempic, or Mounjaro. Compounded drugs bypass the agency's premarket review for safety, efficacy, and quality, so any equivalence claim misrepresents the product's regulatory status. The letters also flagged telehealth firms that branded compounded drugs under their own trademarks without disclosing the compounding pharmacy, a practice FDA said obscures sourcing and accountability. Named recipients included Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, and GoodGirlRx.
The enforcement targets marketing conduct rather than the act of compounding itself. When branded GLP-1 drugs are not in shortage, compounding pharmacies cannot mass-market compounded versions. Telehealth platforms that continued selling compounded semaglutide after shortages ended—Hims & Hers Health among them—faced scrutiny from both FDA and the brand-name manufacturers whose products were being positioned as interchangeable. For operators assessing whether specific peptides are legal to dispense or advertise, the answer now turns on the compound's bulks-list status, the pharmacy's registration, and the precise wording of promotional materials.
Advisory vote runs counter to enforcement pace
Four months after the March letters, FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend six previously restricted peptides for potential inclusion on the Section 503A Bulks List, a step that would allow state-licensed pharmacies to compound those substances for individual patients. FDA staff had recommended against all seven compounds under review, and the advisory vote does not constitute final rulemaking. Compounding of those six peptides remains prohibited until the agency completes formal notice-and-comment proceedings, a process with no published deadline. The Genetic Literacy Project described the panel's composition as reflecting appointments made under the current administration, raising questions about conflicts of interest among voting members.
The enforcement trajectory has not slowed. On June 16, 2026, FDA issued 25 additional warning letters to telehealth companies over compounded GLP-1 marketing claims, bringing the cumulative total past 55 since the campaign began in 2025. Michael Davis, acting director of FDA's Center for Drug Evaluation and Research, stated that "compounded GLP-1 products have not been proven safe, effective, or of consistent quality like FDA-approved drugs," according to Reuters. The June letters cited the same misbranding provisions and the same two categories of violation—sameness claims and obscured sourcing—confirming that the March action was not a one-time escalation but an ongoing enforcement posture.
FDA's February 6 statement had already signaled intent to restrict active pharmaceutical ingredients used in non-approved compounded GLP-1 formulations, targeting the supply chain upstream of marketing. That supply-side pressure narrows the operational space for telehealth platforms built on compounded GLP-1 subscriptions and for the grey-market peptide sellers operating outside the telehealth channel entirely. The 30 companies named in March had their 15-day window expire in late March 2026. FDA has not publicly disclosed which firms submitted corrective responses or whether any seizure or injunction proceedings have been initiated against non-compliant recipients.
